18 completed, 6 recruiting, 6 unknown, 5 not yet recruiting. 22 Phase 2, 15 Phase 3, 4 Phase 4, 3 Not applicable, 3 Phase 1.
Follow Standard Chemotherapy: new trials by email Literature Review of Standard Chemotherapy trials Research Report on Standard Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML) Quizartinib, Chemotherapy, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - Acute Myeloid Leukemia | Phase 4 | Not yet recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 40 | 2026-12-01 | 2026-11-19 |
| Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans Toripalimab, Anlotinib, Standard Chemotherapy - Dermatofibrosarcoma Protuberans (DFSP) | Phase 2 | Not yet recruiting | Yanjie Zhang, MD | 20 | 2026-06-15 | 2026-06-16 |
| Immune Cell Therapy for Advanced Solid Tumors Autologous immune Cells, Standard chemotherapy - Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic) | Phase 1 / Phase 2 | Not yet recruiting | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | 48 | 2025-12-01 | 2025-12-02 |
| Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer TAS-102+bevacizumab+local treatment, Standard chemotherapy - Metastatic Colorectal Cancer (CRC) | Phase 2 | Recruiting | Fudan University | 119 | 2025-02-28 | 2025-08-06 |
| HVA vs IA/DA or VA in the Treatment of ND HR-AML HVA, VA, Standard Chemotherapy - Newly Diagnosed Acute Myeloid Leukemia With High Risk | Phase 3 | Recruiting | Nanfang Hospital, Southern Medical University | 876 | 2025-01-01 | 2025-02-06 |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Quizartinib, Placebo, Chemotherapy - Leukemia | Phase 3 | Active not recruiting | Daiichi Sankyo | 700 | 2024-11-19 | 2026-07-02 |
| Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation Surufatinib, Serplulimab, standard chemotherapy - ESCC, Biliary Tract Cancer | Phase 2 | Not yet recruiting | RenJi Hospital | 80 | 2024-08-10 | 2024-07-31 |
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy GEN1055, Pembrolizumab, Standard Chemotherapy - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 21 | 2024-05-14 | 2026-08-11 |
| The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Huaier granule, chemotherapy drugs - Pancreatic Cancer Resectable | Phase 4 | Recruiting | Xi'an Jiaotong University | 642 | 2024-05-06 | 2024-05-08 |
| Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer Huaier Granule, Capecitabine - Pancreatic Cancer Non-resectable | Phase 4 | Not yet recruiting | Xi'an Jiaotong University | 488 | 2024-05-01 | 2024-04-29 |
| A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity Sparing Approach, experimental chemoradiotherapy, Standard Chemotherapy - Rectal Adenocarcinoma, Non Metastatic | Not applicable | Recruiting | Fondazione del Piemonte per l'Oncologia | 200 | 2024-04-30 | 2026-03-05 |
| A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer Fuzaparib, standard chemotherapy - HR+/HER2- Early Breast Cancer | Phase 2 | Completed | Xijing Hospital | 28 | 2023-03-03 | 2026-04-13 |
| Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 Venetoclax, Placebo, Standard chemotherapy - Acute Myeloid Leukemia | Phase 3 | Recruiting | University of Ulm | 650 | 2022-09-13 | 2026-11-12 |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma | Phase 3 | Completed | PrECOG, LLC. | 214 | 2021-02-18 | 2026-10-22 |
| Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) Azacitidine, Standard Chemotherapy, Allogeneic stem cell transplantation - High-risk MDS | Phase 3 | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 274 | 2020-11-27 | 2025-04-29 |
| Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer UCPVax + Nivolumab, standard chemotherapy - Advanced Non-small Cell Lung Cancer | Phase 2 | Completed | Centre Hospitalier Universitaire de Besancon | 60 | 2020-09-09 | 2025-02-05 |
| Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study Pressurized intraperitoneal aerosol chemotherapy (PIPAC), Standard chemotherapy - Gastric Adenocarcinoma, Cancer Metastatic | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 66 | 2020-06-11 | 2024-09-19 |
| A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer Abemaciclib, Fulvestrant, Standard Chemotherapy - Metastatic Breast Cancer | Phase 4 | Terminated | Eli Lilly and Company | 4 | 2019-08-14 | 2021-08-24 |
| Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer ChemoID Assay, Standard Chemotherapy - Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 3 | Active not recruiting | Cordgenics, LLC | 150 | 2019-07-26 | 2024-08-22 |
| Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy Synchronous resection of primary pancreatic cancer and liver oligometastasis, Standard chemotherapy - Pancreatic Cancer, Liver Metastases | Phase 3 | Unknown | Fudan University | 300 | 2018-07-01 | 2018-10-09 |
Showing 20 of 44. Sign in to see all of them.
Breast Neoplasms (7) · Leukemia, Myeloid, Acute (6) · Carcinoma, Non-Small-Cell Lung (3) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Leukemia (2) · Neoplasms (2) · Rectal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1)
Hoffmann-La Roche (5) · Amgen (2) · Fudan University (2) · University of Ulm (2) · Xi'an Jiaotong University (2) · Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Universitaire de Besancon (1) · Cordgenics, LLC (1) · Daiichi Sankyo (1) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1) · Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1) · Fondazione del Piemonte per l'Oncologia (1) · Genentech, Inc. (1) · Genmab (1)
United States (10) · France (9) · China (7) · Germany (7) · Spain (7) · Italy (6) · Australia (4) · Belgium (4) · Canada (4) · Czechia (4) · Austria (3) · Netherlands (3) · Norway (3) · Poland (3) · United Kingdom (3)
Hartmut Doehner, MD (2) · Zheng Wang, PhD (2) · Ajay K Kakkar, PhD (1) · Anna Nowak, MD (1) · Cary Presant, MD (1) · David SP Tan (1) · Felice Borghi, MD (1) · Guopan Yu (1) · Jalid Sehouli, Prof. Dr. med. (1)
PMID 22377126, PMID 22924433, PMID 24638013, PMID 26342236, PMID 27993804, PMID 28738258, PMID 31818843, PMID 32179448, PMID 32591370, PMID 33358660, PMID 34499875, PMID 35709412, PMID 37187198, PMID 38428265, PMID 39546748, PMID 41146443, PMID 42434847
2023 (2), 2008 (1), 2018 (1)